Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma

NCT06784648 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT06784648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06784648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicentre Phase 1B/2A Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32B) in Combination With Ipilimumab and Pembrolizumab in Participants With Unresectable or Metastatic Melanoma
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 11, 2024
Completion date
July 30, 2027
Enrollment
35 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, melanoma braf v600e/k mutated, melanoma metastatic, melanoma negative for braf, melanoma negative for nras, melanoma of skin, melanoma recurrent, melanoma stage iii or iv, melanomas, uveal melanoma, metastatic